Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease

Behavioural Brain Research

Volumn 271, Issue , 2014, Pages 343-353

  Berghauzen Maciejewska, Klemencja ^a   Kuter, Katarzyna ^a   Kolasiewicz, Wacław ^a   Głowacka, Urszula ^a   Dziubina, Anna ^a   Ossowska, Krystyna ^a   Wardas, Jadwiga ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chronic pramipexole; Depression; Parkinson's disease; Preclinical stages; Rat model

Indexed keywords

DOPAMINE; FLUOXETINE; IMIPRAMINE; PRAMIPEXOLE; TYROSINE 3 MONOOXYGENASE; ANTIDEPRESSANT AGENT; BENZOTHIAZOLE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CAUDATE NUCLEUS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FORCED SWIM TEST; FRONTAL CORTEX; IMMOBILITY; LOCOMOTION; MALE; MOLECULAR INTERACTION; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; MOTOR ACTIVITY; PSYCHOLOGY; SWIMMING; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOTHIAZOLES; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; FLUOXETINE; IMIPRAMINE; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SWIMMING; TREATMENT OUTCOME;

EID: 84903782720     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.06.029     Document Type: Article

References (56)

1. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986, 45:19-34.
2. Lieberman A. Depression in Parkinson's disease-a review. Acta Neurol Scand 2006, 113:1-8.
3. Leentjens A.F.G. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004, 17:120-126.
4. Seppi K., Weintraub D., Coelho M., Perez-Lloret S., Fox S.H., Katzenschlager R., et al. The Movement Disorder Society Evidence-Based Medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011, 26:S42-S80.
5. Lima M.M.S., Martins E.F., Delattre A.M., Proença M.B. Motor and non-motor features of Parkinson's disease-a review of clinical and experimental studies. CNS Neurol Dis-Drug Targets 2012, 11:439-449.
6. Prediger R.D.S., Matheus F.C., Schwarzbold M.L., Lima M.M.S., Vital M.A.B.F. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology 2012, 62:115-124.
7. Lima M.M.S. Sleep disturbances in Parkinson's disease: the contribution of dopamine in REM sleep regulation. Sleep Med Rev 2013, 17:367-375.
8. Ossowska K., Lorenc-Koci E. Depression in Parkinson's disease. Pharmacol Rep 2013, 65:1545-1557.
9. Fang F., Xu Q., Park Y., Huang X., Hollenback A., Blair A., et al. Depression and the subsequent risk of Parkinson's disease in the NIH-AARP diet and health study. Mov Disord 2010, 25:1157-1162.
10. Schuurman A.G., van den Akker M., Ensinck K.T., Metsemakers J.F., Knottnerus J.A., Leentjens A.F. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002, 8:1501-1504.
11. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
12. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain II. Pattern of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122:1437-1448.
13. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991, 50:743-755.
14. Kim S.E., Choi J.Y., Choe Y.S., Choi Y., Lee W.Y. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 2003, 44:870-876.
15. Brooks D.J., Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol 2011, 95:614-628.
16. 11C]DASB. Mov Disord 2008, 23:1776-1780.
17. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
18. Rectorova I., Srovnalova H., Kubikova R., Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and Tower of London task performance in Parkinson's disease. Mov Disord 2008, 23:1580-1587.
19. Vriend C., Raijmakers P., Veltman D.J., van Dijk K.D., van der Werf Y.D., Foncke E.M., et al. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry 2014, 85:159-164.
20. 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2012, 39:1937-1948.
21. Castro A.A., Ghisoni K., Latini A., Quevedo J., Tasca C.I., Prediger R.D.S. Lithium and valproate prevent olfactory discrimination and short-term memory impairment in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav Brain Res 2012, 229:208-215.
22. Santiago R.M., Barbieiro J., Lima M.M.S., Dombrowski P.A., Andreatini R., Vital M.A.B.F. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1104-1114.
23. Vučkovič M.G., Wood R.I., Holschneider D.P., Abernathy A., Togasaki D.M., Smith A., et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008, 32:319-327.
24. Gorton L.M., Vučkovič M.G., Vertelkina N., Petzinger G.M., Jakowec M.W., Wood R. Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav Brain Res 2010, 213:253-262.
25. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., et al. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 2008, 86:2050-2061.
26. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
27. Kuter K., Kolasiewicz W., Gołembiowska K., Dziubina A., Schulze G., Berghauzen K., et al. Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats. Pharmacol Rep 2011, 63:1383-1392.
28. Winter C., von Rumohr A., Mundt A., Petrus D., Klein J., Lee T., et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007, 184:133-141.
29. Chenu F., Dailly E., Bourin M. Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. Eur Neuropsychopharmacol 2007, 17:187-193.
30. Paxinos G., Watson C. The rat brain 2007, Elsevier, Amsterdam. 6th ed.
31. Kolasiewicz W., Kuter K., Berghauzen K., Nowak P., Schulze G., Ossowska K. 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. Brain Res 2012, 1477:59-73.
32. 3 expression in rat striatum. J Pharmacol Sci 2012, 120:133-137.
33. 3 system. J Neural Transm 2000, 107:1369-1379.
34. Maj J., Rogóz Z., Skuza G., Kołodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997, 104:525-533.
35. Willner P., Lappas S., Cheeta S., Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl) 1994, 115:454-462.
36. Rénéric J.-F., Bouvard M., Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 2002, 136:521-532.
37. Wang Y., Cui X.-L., Liu Y.-F., Gao F., Wei D., Li X.-W., et al. LPS inhibits the effect of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1831-1835.
38. Rogóz Z., Skuza G., Legutko B. Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2007, 58:219-234.
39. Van Hoomissen J.D., Chambliss H.O., Holmes P.V., Dishman R.K. Effects of chronic exercise and imipramine on mRNA for BDNF after olfactory bulbectomy in rat. Brain Res 2003, 228-235.
40. Voorn P., Vanderschuren L.J.M.J., Groenewegen H.J., Robbins T.W., Pennartz C.M.A. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 2004, 27:468-474.
41. Stanic D., Finkelstein D.I., Bourke D.W., Drago J., Horne M.K. Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 2003, 18:1175-1188.
42. Ossowska K., Śmiałowska M., Kuter K., Wierońska J., Zieba B., Wardas J., et al. Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. Neuroscience 2006, 141:2155-2165.
43. Huot P., Parent A. Dopaminergic neurons intrinsic to the striatum. J Neurochem 2007, 101:1441-1447.
44. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
45. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
46. Piercey M.F., Hoffmann W.E., Smith M.W., Hyslop D.K. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996, 312:35-44.
47. Siuciak J.A., Fujiwara R.A. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology (Berl) 2004, 175:163-169.
48. Schulte-Herbrüggen O., Vogt M.A., Hörtnagl H., Gass P., Hellweg R. Pramipexole is active in depression tests and modulates monoaminergic transmission, but not brain level of BDNF in mice. Eur J Pharmacol 2012, 677:77-86.
49. Maj J., Rogóz Z., Skuza G., Kołodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 1997, 324:31-37.
50. Chernoloz O., El Mansari M., Blier P. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 2009, 34:651-661.
51. 2 receptor agonist. Eur J Pharmacol 1992, 215:161-170.
52. Page M.E., Detke M.J., Dalvi A., Kirby L.G., Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 1999, 147:162-167.
53. Tucker J.C., File S.E. The effects of tricyclic and atypical antidepressants on spontaneous locomotor activity in rodents. Neurosci Biobehav Rev 1986, 10:115-121.
54. Prisco S., Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 1995, 116:1923-1931.
55. Clark R.N., Ashby C.R., Dewey S.L., Veeraraghavan Ramachandran P., Strecker R.E. Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse 1996, 23:125-131.
56. Mandell A.J., Markham C., Fowler W. Parkinson's syndrome, depression and imipramine. Calif Med 1961, 95:12-14.